The Goldman Sachs Group Issues Pessimistic Forecast for CME Group (NASDAQ:CME) Stock Price

CME Group (NASDAQ:CME) had its price objective cut by stock analysts at The Goldman Sachs Group from $275.00 to $267.00 in a research note issued to investors on Thursday,MarketScreener reports. The brokerage presently has a “sell” rating on the financial services provider’s stock. The Goldman Sachs Group’s price objective points to a potential downside of 5.69% from the company’s previous close.

A number of other equities analysts have also recently commented on CME. Argus reissued a “hold” rating on shares of CME Group in a research note on Wednesday, March 4th. Keefe, Bruyette & Woods began coverage on CME Group in a research report on Wednesday, April 8th. They set a “market perform” rating and a $305.00 price target on the stock. Wall Street Zen raised CME Group from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Jefferies Financial Group reduced their price objective on CME Group from $356.00 to $349.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Finally, Raymond James Financial boosted their target price on CME Group from $310.00 to $320.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $306.35.

CME Group Price Performance

CME stock traded down $2.59 during mid-day trading on Thursday, reaching $283.12. 146,404 shares of the company traded hands, compared to its average volume of 2,285,367. The company has a fifty day moving average price of $305.19 and a 200-day moving average price of $285.92. CME Group has a 52-week low of $257.17 and a 52-week high of $329.16. The company has a market capitalization of $101.53 billion, a P/E ratio of 25.38, a P/E/G ratio of 2.90 and a beta of 0.26. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.03 and a quick ratio of 1.03.

CME Group (NASDAQ:CME) last released its quarterly earnings data on Wednesday, April 22nd. The financial services provider reported $3.36 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.25. The company had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.77 billion. CME Group had a net margin of 62.45% and a return on equity of 14.65%. CME Group’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the business earned $2.80 earnings per share. As a group, analysts anticipate that CME Group will post 12.37 earnings per share for the current year.

Insider Activity

In other CME Group news, Director Martin J. Gepsman sold 300 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $305.90, for a total transaction of $91,770.00. Following the completion of the sale, the director owned 24,999 shares of the company’s stock, valued at $7,647,194.10. This represents a 1.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Jonathan L. Marcus sold 3,291 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $333.37, for a total value of $1,097,120.67. Following the transaction, the general counsel owned 7,192 shares in the company, valued at approximately $2,397,597.04. This represents a 31.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 8,539 shares of company stock valued at $2,713,821. 0.30% of the stock is owned by corporate insiders.

Institutional Trading of CME Group

A number of hedge funds have recently made changes to their positions in the stock. Caldwell Trust Co raised its stake in CME Group by 116.3% during the third quarter. Caldwell Trust Co now owns 93 shares of the financial services provider’s stock valued at $25,000 after buying an additional 50 shares during the last quarter. Asset Dedication LLC raised its holdings in CME Group by 64.9% in the 4th quarter. Asset Dedication LLC now owns 94 shares of the financial services provider’s stock worth $26,000 after acquiring an additional 37 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in CME Group in the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new stake in CME Group during the 4th quarter valued at $27,000. Finally, Elkhorn Partners Limited Partnership bought a new stake in shares of CME Group in the 4th quarter worth $27,000. 87.75% of the stock is owned by institutional investors.

Key CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record volumes and revenue — CME reported record average daily contracts (~36.2M, +22% y/y) and roughly $1.9B in revenue, with adjusted operating income and EPS up year-over-year, highlighting strong franchise demand for listed derivatives. PR Newswire: Record Q1 Results
• Positive Sentiment: Risk-on/risk-off volatility boosts hedging activity — multiple outlets and the earnings call noted elevated market risk is driving record demand for hedging and speculative flows, supporting higher futures/options volumes going forward. MarketWatch: Rising market risk
• Positive Sentiment: Broad-based franchise strength across asset classes — management and transcripts highlight cross-asset volume gains and product mix that sustained margins, reinforcing recurring fee revenue characteristics. TipRanks: Broad-based surge
• Neutral Sentiment: Investor materials and full call transcripts available — analysts and investors are reviewing the detailed call and transcript for forward commentary and expense/capex outlook. Benzinga: Full transcript
• Neutral Sentiment: Questions on sustainability — several previews and follow-ups stress that the key risk is whether elevated volume is persistent or cyclical tied to current market volatility. Investing.com: Sustainability test
• Negative Sentiment: Mixed beats/misses and guidance nuance triggered selling — headlines emphasize that while some consensus figures were beaten, other estimates came in light (revenue/EPS comparisons vary by source), prompting a pullback in the stock. Yahoo Finance: Sales below estimates
• Negative Sentiment: Valuation worries — analysts and commentary (Seeking Alpha, Zacks) note the stock still looks expensive on forward multiples despite the beat on volume, increasing sensitivity to any volume slowdown. Seeking Alpha: Valuation concerns
• Negative Sentiment: Institutional repositioning — some funds reduced CME exposure in recent filings, a factor that can add selling pressure if investors reweight after the quarter. QuiverQuant: Fund reductions

CME Group Company Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.